H. Lundbeck A — AGM Information 2011

Mar 30, 2011

DK-2500 Valby, Copenhagen Fax +45 36 43 82 62 www.lundbeck.com CVR number: 56759913

Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com

Corporate Release No 432

30 March 2011

H. Lundbeck A/S held its Annual General Meeting on 30 March 2011 at the company's registered office

At the general meeting the report by the Supervisory Board was adopted and the Annual Report was approved.

The general meeting approved the remuneration for the Supervisory Board for the current financial year.

The general meeting approved the dividend of DKK 3.77 per share of DKK 5 nominal value proposed by the Supervisory Board.

Thorleif Krarup, Peter Kürstein, Mats Pettersson and Jes Østergaard were re-elected and Christian Dyvig and Håkan Björklund were elected to the Supervisory Board. Immediately after the general meeting, the Supervisory Board elected Mats Pettersson Chairman and Thorleif Krarup Vice-Chairman of the Supervisory Board.

After having elected its Chairman and Vice-Chairman, the Supervisory Board appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Peter Kürstein (committee chairman), Thorleif Krarup and Mats Pettersson were elected as members of the Audit Committee. Mats Pettersson (committee chairman), Håkan Bjørklund and Jes Østergaard were elected as members of the Remuneration Committee. Jes Østergaard (committee chairman), Håkan Bjørklund and Christian Dyvig were elected as members of the Scientific Committee.

The Supervisory Board of H. Lundbeck A/S will hereafter comprise:

• Mats Pettersson (Chairman)
• Thorleif Krarup (Vice-Chairman)
• Peter Kürstein
• Jes Østergaard
• Christian Dyvig
• Håkan Björklund
• Mona Elisabeth Elster (employee representative)
• Jørn Møller Mayntzhusen (employee representative)
• Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the company's auditor.

The proposal by the Supervisory Board to adapt the Company's "Remuneration guidelines for the Supervisory Board and the Executive Management of H. Lundbeck A/S" so as to comply with the Recommendations on Corporate Governance was approved.

No other business was transacted at the general meeting.

The Supervisory Board

The content of this release will have no influence on the Lundbeck Group's financial result for 2011.

Lundbeck contacts

Investors: Media:

Palle Holm Olesen Mads Kronborg Chief Specialist, Investor Relations Media Relations Manager +45 36 43 24 26 +45 36 43 28 51

Magnus Thorstholm Jensen Investor Relations Officer +45 36 43 38 16

Jacob Tolstrup Vice President +1 847 282 5713

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.